Global Antibody Therapeutics Market Size study, by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, Polyclonal Antibody), by Route of Administration (Intravenous, Subcutaneous), by Source (Chimeric, Human, Humanized), by Disease Areas

Global Antibody Therapeutics Market Size study, by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, Polyclonal Antibody), by Route of Administration (Intravenous, Subcutaneous), by Source (Chimeric, Human, Humanized), by Disease Areas (Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, Osteology), by End User (Hospitals, Long-term Care Facilities) and Regional Forecasts 2022-2032

The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system’s ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.

The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.

Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.

Major market players included in this report are:

AbbVie Inc.

AbCellera Biologics Inc.

Adaptimmune Therapeutics PLC

ADC Therapeutics SA

Aenova Holding GmbH

Almac Group Limited

Amgen Inc.

Antikor Biopharma

Argenx SE

Astellas Pharma Inc.

AstraZeneca PLC

Baxter International Inc.

Bayer AG

Becton, Dickinson and Company

Bio-Rad Laboratories, Inc.

The detailed segments and sub-segment of the market are explained below:

By Format:

Antibody Fragment

Bispecific Antibody

Monoclonal Antibody

Polyclonal Antibody

By Route of Administration:

Intravenous

Subcutaneous

By Source:

Chimeric

Human

Humanized

By Disease Areas:

Autoimmune & Inflammatory Diseases

Hematology

Immunology

Neurology

Oncology

Osteology

By End User:

Hospitals

Long-term Care Facilities

By Region:

North America:

U.S.

Canada

Europe:

UK

Germany

France

Spain

Italy

ROE

Asia Pacific:

China

India

Japan

Australia

South Korea

RoAPAC

Latin America:

Brazil

Mexico

Middle East & Africa:

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.